These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 24780456)

  • 1. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
    Yamout H; Lazich I; Bakris GL
    Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
    Sarafidis PA; Ruilope LM
    Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
    Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limitations of angiotensin inhibition.
    Nobakht N; Kamgar M; Rastogi A; Schrier RW
    Nat Rev Nephrol; 2011 Jun; 7(6):356-9. PubMed ID: 21502972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function].
    Ritz E
    MMW Fortschr Med; 2004 Sep; 146(38):12. PubMed ID: 15532423
    [No Abstract]   [Full Text] [Related]  

  • 15. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
    Schjoedt KJ
    Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
    Barnas U; Mayer G
    Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.